Prescription Required
Formulation: Capsule
(Brand Option)
Select the prescribed dosage
Select the quantity to see the price.
Prescription Required
Formulation: Capsule
Select the quantity to see the price.
* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
One-Alpha is a prescription medication used to manage certain disorders involving calcium, phosphorus, and bone metabolism, particularly in patients with chronic kidney disease.
It contains alfacalcidol, a synthetic vitamin D analogue that helps the body regulate calcium and phosphorus levels and maintain healthy bones.
Unlike ordinary vitamin D supplements, One-Alpha is designed for patients whose bodies have difficulty maintaining normal calcium balance because of certain medical conditions.
Alfacalcidol is converted by the liver into calcitriol, the active form of vitamin D. This active form helps the intestines absorb calcium and phosphorus and supports normal bone mineralization.
In Canada, One-Alpha is approved for adults with chronic renal failure to manage low blood calcium levels, secondary hyperparathyroidism, and renal osteodystrophy.
One-Alpha helps regulate calcium metabolism and supports bone health in patients with certain kidney-related disorders. It requires medical supervision because excessive treatment may cause dangerously high calcium levels.Â
One-Alpha is used to manage renal osteodystrophy, a bone disorder associated with chronic kidney disease.
The kidneys normally help convert vitamin D into its active form, which is necessary for maintaining healthy calcium and phosphorus levels.
When kidney function becomes impaired, the body may struggle to produce enough active vitamin D.
This can reduce calcium absorption from food and contribute to abnormal calcium and phosphorus levels in the bloodstream.
Over time, these imbalances may affect bone strength and structure.
Patients with renal osteodystrophy may experience bone pain, muscle weakness, increased fracture risk, and other skeletal complications.
One-Alpha helps compensate for impaired vitamin D activation by providing alfacalcidol, which the liver converts into active vitamin D.
This supports calcium absorption and helps regulate the hormonal processes involved in bone metabolism.
Your healthcare provider will monitor blood calcium, phosphate, and parathyroid hormone levels to assess treatment effectiveness.
One-Alpha helps manage bone and mineral abnormalities associated with chronic kidney disease, reducing some of the metabolic disturbances that contribute to renal osteodystrophy.
One-Alpha may be prescribed to treat hypocalcemia in adults with chronic renal failure.
Hypocalcemia occurs when calcium levels in the bloodstream fall below the normal range.
Calcium is an essential mineral involved in bone strength, muscle contraction, nerve signaling, and normal heart function.
When calcium levels become too low, patients may experience muscle cramps, tingling sensations, numbness, or muscle spasms.
Severe hypocalcemia may cause seizures or abnormal heart rhythms.
Patients with chronic kidney disease are particularly susceptible because their kidneys may not activate vitamin D effectively.
Without sufficient active vitamin D, the intestines absorb less calcium from food.
One-Alpha helps increase calcium absorption by providing a vitamin D analogue that can be converted into active vitamin D by the liver.
This may help restore calcium levels and reduce symptoms associated with hypocalcemia.
However, excessive treatment can raise calcium levels too high, which may also be dangerous.
One-Alpha helps manage low blood calcium in patients with chronic renal failure. Regular blood tests are essential to ensure calcium levels remain within a safe range.
One-Alpha is also used to manage secondary hyperparathyroidism in adults with chronic renal failure.
Secondary hyperparathyroidism occurs when the parathyroid glands produce excessive amounts of parathyroid hormone (PTH) in response to disturbances in calcium, phosphorus, and vitamin D metabolism.
The parathyroid glands are small glands located in the neck that help regulate calcium levels in the blood.
In patients with chronic kidney disease, reduced active vitamin D production and abnormal phosphorus handling may contribute to increased PTH secretion.
When PTH remains elevated for a prolonged period, it can increase bone turnover and weaken bone structure.
This may contribute to bone pain, skeletal abnormalities, and a higher risk of fractures.
One-Alpha helps increase active vitamin D activity in the body, supporting calcium absorption and helping suppress excessive PTH production.
Your healthcare provider may recommend regular measurements of calcium, phosphate, and PTH levels to determine whether treatment is effective.
One-Alpha helps control secondary hyperparathyroidism associated with chronic kidney disease by improving vitamin D activity and helping regulate parathyroid hormone levels.
One-Alpha is a vitamin D analogue, but it is important to understand that it is not the same as ordinary vitamin D supplements.
Common nutritional vitamin D deficiency occurs when the body does not receive enough vitamin D from sunlight, food, or supplements.
This type of deficiency is usually treated with vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol), depending on the patient’s needs.
One-Alpha works differently because it is designed to increase active vitamin D activity in patients with certain disorders of calcium metabolism.
In Canada, One-Alpha is not specifically approved as a routine treatment for uncomplicated nutritional vitamin D deficiency.
However, alfacalcidol may be used in certain countries for selected vitamin D-related metabolic bone disorders, including particular forms of rickets and osteomalacia.
These conditions require individualized medical assessment and treatment.
One-Alpha should not be used as a substitute for ordinary vitamin D supplements unless specifically prescribed. It is primarily used for calcium and bone metabolism disorders associated with impaired kidney function.Â
Rickets and osteomalacia are bone disorders associated with inadequate mineralization.
Rickets affects growing bones in children, while osteomalacia affects mature bones, primarily in adults.
These conditions may develop because of vitamin D deficiency, impaired vitamin D metabolism, or certain abnormalities involving calcium and phosphorus.
Symptoms of osteomalacia may include bone pain, muscle weakness, and an increased risk of fractures.
Children with rickets may develop bone deformities, delayed growth, or skeletal abnormalities.
In certain countries, alfacalcidol is used to treat selected forms of rickets and osteomalacia, particularly when the body has difficulty activating vitamin D normally.
However, the underlying cause must be identified before treatment begins.
For example, ordinary nutritional vitamin D deficiency is generally treated with conventional vitamin D supplements rather than alfacalcidol.
In Canada, One-Alpha is not authorized for pediatric use because its safety and effectiveness in children have not been established under the Canadian product monograph.
One-Alpha may be used for selected metabolic bone disorders in certain countries, but its use depends on the diagnosis and local prescribing approvals.Â
One-Alpha contains alfacalcidol, a vitamin D analogue that helps regulate the body’s calcium and phosphorus balance.
Vitamin D is necessary for normal bone development, mineral absorption, and several other physiological processes.
Under normal conditions, vitamin D undergoes processing in the liver and kidneys before becoming fully active.
The kidneys perform an important step in this activation process.
In patients with chronic kidney disease, this step may become impaired.
Alfacalcidol helps address this problem because it can be converted into active vitamin D by the liver without requiring the usual kidney activation step.
Increases Calcium Absorption
Active vitamin D helps the intestines absorb calcium from food.
This supports normal blood calcium levels and helps maintain healthy bones.
Supports Phosphorus Absorption
Active vitamin D also increases intestinal phosphorus absorption.
Phosphorus is an important mineral involved in bone formation and many cellular functions.
However, patients with kidney disease may have difficulty removing excess phosphorus, so blood levels must be carefully monitored.
Helps Regulate Parathyroid Hormone
One-Alpha helps reduce excessive PTH activity in appropriate patients with chronic kidney disease.
This can help control abnormal bone turnover associated with secondary hyperparathyroidism.
Supports Bone Mineralization
Calcium and phosphorus are essential for maintaining strong bones.
By improving active vitamin D activity and helping regulate mineral metabolism, One-Alpha supports normal bone mineralization.
One-Alpha works by providing a form of vitamin D that the liver converts into active vitamin D, helping regulate calcium absorption, parathyroid hormone activity, and bone metabolism.
The time needed for One-Alpha to produce noticeable benefits depends on the condition being treated, the prescribed dosage, kidney function, and individual response.
After administration, alfacalcidol is converted into active vitamin D by the liver.
This active form begins influencing calcium absorption and mineral metabolism.
However, improvements in blood calcium and parathyroid hormone levels may take several days or longer, depending on the patient’s condition.
Patients receiving treatment for renal osteodystrophy may require a longer period before noticeable improvements in bone-related symptoms occur.
Because the effects of One-Alpha are closely related to calcium and phosphorus balance, healthcare providers generally rely on blood tests rather than symptoms alone to evaluate treatment effectiveness.
Your healthcare provider may adjust the dosage based on calcium, phosphate, parathyroid hormone, and other laboratory results.
One-Alpha begins affecting calcium metabolism after it is activated in the body, but the time needed to achieve stable mineral levels and improve bone-related symptoms varies between patients.
One-Alpha is available in different formulations, including capsules, oral drops, and injectable preparations, depending on the country and product availability.
The dosage depends on kidney function, the condition being treated, blood calcium levels, and individual response.
One-Alpha may cause hypercalcemia, a condition in which calcium levels in the blood become too high.
Symptoms of hypercalcemia may include nausea, vomiting, constipation, excessive thirst, frequent urination, muscle weakness, and confusion.
Severe or prolonged hypercalcemia may contribute to kidney damage, abnormal heart rhythms, and calcium deposits in body tissues.
One-Alpha should not be used in patients with high blood calcium, high blood phosphate, or evidence of vitamin D overdose, according to Canadian prescribing information.
Because of these risks, regular blood tests are essential during treatment.
Do not take additional vitamin D or calcium supplements unless your healthcare provider recommends them.
Take One-Alpha exactly as prescribed and attend all recommended blood tests. Contact your healthcare provider if you experience persistent nausea, excessive thirst, frequent urination, unusual weakness, or other symptoms of elevated calcium levels.
One-Alpha is a prescription medication used to manage certain conditions involving abnormal calcium, phosphorus, and bone metabolism, particularly in adults with chronic kidney disease.
It contains alfacalcidol, a vitamin D analogue that helps the body absorb calcium and regulate mineral levels. After administration, alfacalcidol is converted by the liver into calcitriol, the active form of vitamin D.
One-Alpha is available in different formulations, including oral capsules, oral drops, and intravenous injections.
The appropriate dosage depends on the patient’s kidney function, blood calcium levels, parathyroid hormone levels, and individual response to treatment.
One-Alpha capsules and oral drops are usually taken once daily, with or without food, according to the prescribed instructions.
Because excessive alfacalcidol may cause dangerously high calcium levels, your healthcare provider will adjust your dosage based on regular blood tests.
Take One-Alpha exactly as prescribed. Do not increase, decrease, or stop taking the medication without consulting your healthcare provider.Â
One-Alpha capsules should be taken by mouth according to your healthcare provider’s instructions.
Swallow the capsule whole with a glass of water or another suitable drink.
The capsules may be taken with or without food. If you experience mild stomach discomfort, taking the medication with a meal may help.
Do not crush, chew, open, or divide the capsules because they are intended to be swallowed whole.
One-Alpha is generally taken once daily, preferably at approximately the same time each day.
Taking the medication consistently helps maintain your prescribed treatment schedule.
The dosage may be adjusted over time depending on your blood calcium, phosphate, and parathyroid hormone levels.
Swallow One-Alpha capsules whole and take them at approximately the same time each day. Follow your prescribed dosage carefully.
One-Alpha oral drops provide an alternative for patients who have difficulty swallowing capsules or require a liquid formulation.
The oral drops contain alfacalcidol and must be measured carefully to ensure the correct dose.
When using One-Alpha oral drops, remove the protective cap from the bottle, but do not remove the plastic dropper inserted into the bottle opening.
Hold the bottle vertically upside down so the liquid can flow through the dropper.
If the liquid does not begin flowing, gently tap the bottle. Do not shake the bottle to force the drops out.
Measure the exact number of drops prescribed by your healthcare provider or pharmacist.
The oral drops can be taken with or without food.
Because alfacalcidol is a potent vitamin D analogue, even small dosing errors may affect blood calcium levels.
Do not estimate your dose or use a different measuring device unless your pharmacist confirms that it is appropriate.
Use One-Alpha oral drops only in the prescribed amount. Follow the bottle instructions carefully to avoid taking too much medication.Â
One-Alpha is also available as an intravenous injection for selected patients receiving hemodialysis.
Hemodialysis is a medical treatment that removes waste products and excess fluid from the bloodstream when the kidneys cannot perform these functions adequately.
The injectable formulation is administered by a trained healthcare professional and is not intended for self-injection.
The dosage is determined based on the patient’s medical condition, laboratory results, and dialysis schedule.
Your healthcare team will monitor calcium, phosphate, and other relevant blood levels during treatment.
Do not attempt to administer One-Alpha injection yourself unless an appropriately authorized healthcare professional has provided a specific supervised treatment arrangement.
One-Alpha injection should only be administered by qualified healthcare professionals, usually in connection with hemodialysis treatment.
The recommended dosage of One-Alpha varies depending on the condition being treated and the patient’s laboratory results.
For adults with chronic renal failure, treatment is generally started at a low dose and adjusted gradually according to blood calcium levels and other measurements.
The Canadian product monograph provides an initial oral dosage of approximately 0.25 to 0.5 micrograms daily for appropriate adult patients, with subsequent adjustments based on treatment response.
Some patients may require higher or lower doses depending on the severity of their condition, kidney function, and mineral balance.
Older adults may require additional caution because they are more likely to have other medical conditions or take medications that affect calcium metabolism.
The dosage should never be determined solely by symptoms because abnormal calcium levels can develop before obvious symptoms appear.
Your healthcare provider may increase, reduce, or temporarily stop treatment based on your laboratory results.
One-Alpha dosing must be individualized. Never adjust the number of capsules or drops without instructions from your healthcare provider.
The appropriate starting dose also depends on whether the patient receives dialysis. According to the Canadian product monograph, adults with chronic kidney failure who are not yet receiving dialysis may begin with 0.25 micrograms daily, while patients receiving dialysis and taking oral One-Alpha may begin with 1 microgram daily. These are prescribing reference doses, not instructions to adjust medication independently.Â
Yes. One-Alpha capsules and oral drops can generally be taken with or without food.
Food is not required for the medication to work. However, taking One-Alpha with a meal may make it easier to remember your daily dose.
Patients with chronic kidney disease may need to follow a specific diet to maintain appropriate calcium and phosphorus levels.
Your healthcare provider or renal dietitian may recommend adjustments to dietary calcium, phosphate, or other nutrients based on your blood test results.
Do not make major changes to your calcium intake without medical advice.
One-Alpha can be taken with or without food, but follow any dietary recommendations provided by your healthcare team.
If you forget to take a dose of One-Alpha, take it as soon as you remember.
However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular treatment schedule.
Do not take two doses together to make up for a missed dose.
Taking more alfacalcidol than prescribed may increase blood calcium levels and cause potentially serious complications.
If you frequently miss doses, consider setting a medication reminder or taking One-Alpha at the same time each day.
Never double your One-Alpha dose to make up for a missed dose. Contact your healthcare provider or pharmacist if you are unsure when to take your next dose.Â
Regular blood tests are essential because One-Alpha affects calcium and phosphorus metabolism.
Although these minerals are necessary for healthy bones, excessive levels can damage the kidneys, blood vessels, heart, and other tissues.
Your healthcare provider may monitor calcium, phosphate, parathyroid hormone (PTH), kidney function, and alkaline phosphatase levels.
The frequency of monitoring depends on your treatment stage, kidney function, and laboratory results.
Blood tests may be required more frequently when starting One-Alpha or adjusting the dosage.
Once your mineral levels are stable, your healthcare provider may recommend a different monitoring schedule.
Attend all recommended blood tests while taking One-Alpha. Laboratory monitoring helps your healthcare provider determine whether your dosage is safe and effective.
Do not take additional calcium or vitamin D supplements unless your healthcare provider specifically recommends them.
One-Alpha increases the body’s ability to absorb calcium.
Combining it with excessive calcium or other vitamin D products may increase the risk of hypercalcemia, which means calcium levels in the blood become too high.
Some patients with chronic kidney disease may require calcium supplements as part of their treatment plan.
However, the appropriate amount depends on dietary intake, laboratory results, and other medications.
Your healthcare provider may also recommend phosphate binders to help control phosphorus levels.
Do not start over-the-counter vitamin D products, calcium supplements, or mineral-containing antacids without checking for possible interactions.
Avoid taking additional vitamin D or calcium supplements with One-Alpha unless directed by your healthcare provider.Â
Taking excessive amounts of One-Alpha may cause hypercalcemia, hyperphosphatemia, or increased calcium levels in the urine.
Hypercalcemia occurs when calcium builds up in the bloodstream beyond the normal range.
Possible symptoms include nausea, vomiting, constipation, loss of appetite, excessive thirst, frequent urination, muscle weakness, and unusual fatigue.
Severe hypercalcemia may cause confusion, dehydration, kidney problems, or abnormal heart rhythms.
These complications may become dangerous if they are not recognized and treated promptly.
If you suspect that you have taken more One-Alpha than prescribed, contact your healthcare provider or poison control center immediately, even if you do not have symptoms.
Do not take extra One-Alpha. Seek urgent medical advice if an overdose is suspected, and obtain emergency care for severe confusion, fainting, or abnormal heart rhythms.
Do not stop taking One-Alpha without consulting your healthcare provider.
One-Alpha is often prescribed to manage ongoing abnormalities in calcium and bone metabolism associated with chronic kidney disease.
Although symptoms may improve during treatment, this does not necessarily mean that calcium, phosphate, or parathyroid hormone levels have returned to a stable range.
Stopping treatment without medical guidance may allow the underlying mineral imbalance to return.
However, your healthcare provider may need to reduce or temporarily discontinue One-Alpha if blood tests show excessive calcium levels.
Do not independently restart a discontinued dose without instructions.
Continue taking One-Alpha according to your prescribed treatment plan. Any dosage changes should be guided by your healthcare provider and laboratory results.
One-Alpha has a narrow therapeutic margin, meaning the difference between an effective dose and an excessive dose may be relatively small.
Because of this, careful dosage selection and regular monitoring are necessary.
Tell your healthcare provider if you have a history of kidney stones, elevated calcium levels, heart disease, or other conditions affecting mineral metabolism.
Also provide a complete list of medications and supplements, especially calcium products, vitamin D supplements, thiazide diuretics, magnesium-containing antacids, and heart medications such as digoxin.
One-Alpha should not be used when blood tests show hypercalcemia, hyperphosphatemia, or evidence of vitamin D overdose.
Take One-Alpha exactly as prescribed, avoid unapproved supplements, attend regular blood tests, and report symptoms of elevated calcium promptly.
One-Alpha (Alfacalcidol) is available in the following forms and strength:
One-Alpha is a prescription medication used to manage disorders involving calcium, phosphorus, and bone metabolism, particularly in adults with chronic kidney disease.
It contains alfacalcidol, a vitamin D analogue that the liver converts into calcitriol, the active form of vitamin D. This helps the body absorb calcium and regulate mineral levels necessary for maintaining healthy bones.
Although One-Alpha can help manage low blood calcium, secondary hyperparathyroidism, and renal osteodystrophy, it must be used carefully because excessive amounts may cause serious complications.
One-Alpha has a narrow therapeutic margin, meaning the difference between an effective dose and an excessive dose can be relatively small.
One-Alpha requires regular blood tests and careful dosage adjustments. Do not increase, decrease, or stop taking the medication without medical guidance, except when instructed to seek urgent care for a suspected serious reaction.Â
One of the most important precautions when taking One-Alpha is the risk of hypercalcemia.
Hypercalcemia occurs when calcium levels in the bloodstream become higher than normal.
One-Alpha increases the body’s ability to absorb calcium from food and supplements. Although this effect is beneficial for patients with certain calcium metabolism disorders, excessive calcium absorption can become dangerous.
The risk of hypercalcemia may increase when One-Alpha is taken at higher-than-prescribed doses, combined with excessive calcium supplements, or used in patients whose calcium levels are already elevated.
Symptoms may include nausea, vomiting, constipation, loss of appetite, excessive thirst, frequent urination, muscle weakness, and unusual fatigue.
More severe hypercalcemia may cause confusion, dehydration, abnormal heart rhythms, or worsening kidney function.
One-Alpha should not be used when blood tests show hypercalcemia.
Your healthcare provider will monitor calcium levels regularly and may reduce or temporarily discontinue treatment if calcium becomes elevated.
Contact your healthcare provider promptly if you develop persistent nausea, excessive thirst, frequent urination, or muscle weakness. Seek emergency medical attention for severe confusion, fainting, or abnormal heart rhythms.
One-Alpha should not be used when blood tests show hyperphosphatemia, according to Canadian prescribing information.
Hyperphosphatemia occurs when phosphorus levels in the bloodstream become too high.
Phosphorus is an essential mineral involved in bone formation and normal cellular function.
However, patients with chronic kidney disease may have difficulty removing excess phosphorus from their bodies.
Because One-Alpha increases active vitamin D activity, it may also increase phosphorus absorption from food.
When calcium and phosphorus levels are both elevated, the risk of abnormal mineral deposits in blood vessels and other tissues may increase.
Your healthcare provider may recommend dietary phosphorus restrictions or medications called phosphate binders to help manage phosphorus levels.
Regular blood tests are necessary because high phosphorus levels may not cause noticeable symptoms during the early stages.
Follow your prescribed dietary recommendations and attend regular blood tests to prevent excessive phosphorus levels and related complications.
One-Alpha is commonly prescribed for certain bone and mineral disorders associated with chronic kidney disease.
However, patients with impaired kidney function require careful monitoring because they may be more susceptible to abnormalities in calcium and phosphorus balance.
Prolonged hypercalcemia can contribute to kidney stone formation and may worsen existing kidney problems.
Kidney stones develop when minerals, including calcium, accumulate and form hard deposits within the urinary tract.
Symptoms may include severe pain in the back or side, nausea, vomiting, or blood in the urine.
Excess calcium may also accumulate within kidney tissue, leading to a condition called nephrocalcinosis.
Over time, this may contribute to further deterioration of kidney function.
Your healthcare provider may monitor kidney function through blood tests, urine tests, and other assessments.
Inform your healthcare provider if you have a history of kidney stones. Seek prompt medical attention if you develop severe flank pain, blood in your urine, or a significant reduction in urination.
Patients with heart disease should use One-Alpha cautiously because significant changes in calcium levels can affect the heart.
Calcium plays an essential role in maintaining normal heart muscle contractions and electrical activity.
When blood calcium levels become excessively high, the risk of abnormal heart rhythms may increase.
This is particularly concerning for patients who already have cardiovascular disease or take medications that affect heart function.
Prolonged hypercalcemia may also contribute to calcium deposits in blood vessels and heart valves.
These deposits can affect normal circulation and may worsen existing cardiovascular conditions.
Patients taking cardiac glycosides, such as digoxin, require special caution because hypercalcemia can increase the risk of serious arrhythmias.
Your healthcare provider may recommend closer monitoring of calcium levels and heart function.
Tell your healthcare provider if you have heart disease or take digoxin. Seek emergency medical attention if you experience chest pain, fainting, or a rapid or irregular heartbeat accompanied by severe weakness.
Prolonged elevations in calcium and phosphorus levels may cause calcium to accumulate in tissues outside the bones.
This condition is called ectopic calcification.
Calcium deposits may develop in blood vessels, kidneys, eyes, and other soft tissues.
When calcium accumulates in blood vessel walls, it may reduce their flexibility and contribute to cardiovascular problems.
Calcium deposits in the kidneys may worsen kidney function, while deposits in certain eye structures may contribute to irritation or visual disturbances.
Patients with chronic kidney disease may be particularly vulnerable because their bodies often have difficulty maintaining normal mineral balance.
Your healthcare provider may monitor calcium and phosphorus levels and recommend additional examinations when necessary.
Regular monitoring of calcium and phosphorus is essential to reduce the risk of abnormal calcium deposits in blood vessels, kidneys, and other tissues.Â
One-Alpha should not be used when there is evidence of vitamin D overdose.
Because alfacalcidol is converted into active vitamin D, taking excessive amounts may cause serious disturbances in calcium metabolism.
Patients should not combine One-Alpha with other vitamin D products or vitamin D analogues unless specifically directed by their healthcare provider.
Examples include vitamin D3 supplements, vitamin D2 supplements, calcitriol, and other prescription vitamin D preparations.
Combining these products may increase the risk of hypercalcemia.
Symptoms of excessive vitamin D activity may include nausea, vomiting, constipation, excessive thirst, frequent urination, weakness, and confusion.
Even over-the-counter supplements may contain significant amounts of vitamin D.
Do not take additional vitamin D supplements while using One-Alpha unless your healthcare provider specifically recommends them.
Patients taking One-Alpha may require an appropriate amount of dietary calcium to support treatment.
However, excessive calcium intake can increase the risk of hypercalcemia.
Calcium may come from food, dietary supplements, certain antacids, and medications.
Your healthcare provider will determine whether calcium supplementation is necessary based on your medical condition and blood test results.
Patients with chronic kidney disease may also need to follow specific dietary recommendations concerning calcium and phosphorus.
Do not independently increase your calcium intake or take additional calcium supplements to improve bone health.
Excess calcium may accumulate in the bloodstream and contribute to kidney damage or other complications.
Take calcium supplements only when recommended by your healthcare provider, and follow your prescribed dietary calcium limits.
One-Alpha may interact with certain prescription medications, over-the-counter products, and supplements.
Some interactions can increase the risk of hypercalcemia, while others may affect the absorption or metabolism of alfacalcidol.
Thiazide Diuretics
Thiazide diuretics, such as hydrochlorothiazide, may reduce calcium excretion through the kidneys.
When combined with One-Alpha, these medications may increase the risk of elevated blood calcium levels.
Digoxin and Other Cardiac Glycosides
Patients taking digoxin require particular caution because hypercalcemia may increase the risk of dangerous heart rhythm disturbances.
Anticonvulsant Medications
Certain seizure medications, including phenytoin, carbamazepine, phenobarbital, and primidone, may increase the metabolism of alfacalcidol and reduce its effects.
Your healthcare provider may need to reassess your dosage or laboratory monitoring.
Magnesium-Containing Antacids
Patients taking One-Alpha should avoid magnesium-containing antacids unless specifically directed by their healthcare provider.
Combining these products may increase the risk of elevated magnesium levels, particularly in patients with impaired kidney function.
Aluminum-Containing Medications
Certain aluminum-containing products, including some antacids and sucralfate, may increase the risk of aluminum accumulation and toxicity during alfacalcidol treatment.
Medications That Reduce Absorption
Cholestyramine and mineral oil may interfere with the absorption of oral One-Alpha.
Your healthcare provider or pharmacist may recommend separating the administration times.
Tell your healthcare provider and pharmacist about all medications, vitamins, herbal supplements, and over-the-counter products you take before starting One-Alpha.Â
One-Alpha should be used cautiously in patients with sarcoidosis or other granulomatous diseases.
Sarcoidosis is an inflammatory condition characterized by the formation of small clusters of immune cells called granulomas.
These granulomas can affect organs such as the lungs, lymph nodes, skin, and eyes.
Some granulomatous diseases can increase the body’s sensitivity to vitamin D and contribute to excessive calcium production or absorption.
As a result, patients with these conditions may be more susceptible to hypercalcemia when taking vitamin D analogues.
Your healthcare provider may recommend additional calcium monitoring or consider alternative treatment depending on your condition.
Inform your healthcare provider if you have sarcoidosis or another granulomatous disease before taking One-Alpha.
One-Alpha should generally be avoided during pregnancy unless a healthcare provider determines that treatment is clearly necessary.
There is limited information about the safety of alfacalcidol during human pregnancy.
Animal studies have identified reproductive risks, and excessive calcium levels during pregnancy may affect fetal development.
Because One-Alpha increases active vitamin D activity, uncontrolled treatment may lead to hypercalcemia.
Your healthcare provider will consider the severity of your underlying condition and the potential benefits and risks before recommending treatment.
If One-Alpha is considered necessary, careful monitoring of calcium and phosphorus levels may be required.
Consult your healthcare provider before taking One-Alpha during pregnancy. Do not start or change treatment without medical guidance.Â
Breastfeeding should be avoided during One-Alpha treatment according to the Canadian product monograph.
Alfacalcidol or its active metabolites may enter breast milk and potentially affect calcium metabolism in a nursing infant.
Excessive vitamin D activity in an infant may cause abnormal calcium levels and related complications.
Your healthcare provider will consider whether One-Alpha treatment is necessary and discuss appropriate feeding options.
If you are planning to breastfeed, inform your healthcare provider before starting treatment.
Do not stop a necessary prescription medication independently.
Breastfeeding is not recommended during One-Alpha treatment under Canadian prescribing guidance. Discuss alternative feeding arrangements or treatment options with your healthcare provider.Â
One-Alpha is not authorized for pediatric use in Canada.
The safety and effectiveness of One-Alpha in patients younger than 18 years have not been established under the Canadian product monograph.
Children may be particularly sensitive to disturbances in calcium and phosphorus metabolism because these minerals are essential for normal growth and bone development.
Excessive calcium levels may contribute to kidney problems and other complications.
Although alfacalcidol may be prescribed for certain pediatric disorders in other countries, treatment requirements and regulatory approvals vary.
Children should not receive One-Alpha without specialist assessment and an appropriate treatment plan.
One-Alpha is not approved for patients younger than 18 years in Canada. Pediatric treatment requires specialist guidance and should not be initiated independently.
Older adults may require additional caution during treatment with One-Alpha because they are more likely to have other medical conditions or take several medications.
Age-related changes in kidney function may affect calcium and phosphorus balance.
Older patients may also be more susceptible to complications associated with hypercalcemia, including dehydration, confusion, weakness, and abnormal heart rhythms.
The Canadian product monograph states that sufficient information is not available to establish an authorized indication for patients older than 65 years.
If a healthcare provider considers alfacalcidol necessary for an older patient, careful assessment and monitoring are important.
Older adults should use One-Alpha only under individualized medical supervision, with regular evaluation of calcium levels, kidney function, and potential medication interactions.Â
Regular laboratory monitoring is one of the most important precautions during One-Alpha treatment.
Because alfacalcidol affects mineral metabolism, blood calcium and phosphorus levels may change even before symptoms become noticeable.
Your healthcare provider may recommend tests to measure calcium, phosphorus, magnesium, creatinine, blood urea nitrogen, alkaline phosphatase, and parathyroid hormone levels.
These tests help evaluate treatment effectiveness and identify possible complications.
Monitoring may be more frequent when treatment begins or the dosage is adjusted.
Patients undergoing dialysis may require particularly close monitoring during dosage adjustments.
If calcium levels become elevated, your healthcare provider may reduce or temporarily discontinue One-Alpha until they return to an acceptable range.
Never skip recommended blood tests. Regular monitoring is essential for identifying high calcium or phosphorus levels before serious complications occur.Â
Do not take One-Alpha if you are allergic to alfacalcidol or any other ingredient in the formulation.
Allergic reactions may cause itching, skin rash, hives, or swelling.
One-Alpha capsules contain sesame oil, which is particularly important for patients with a known sesame allergy.
Different formulations may contain different inactive ingredients, so patients should review the product ingredients with their pharmacist.
In rare cases, a severe allergic reaction may cause swelling of the face, lips, tongue, or throat and difficulty breathing.
Do not take One-Alpha if you have a known allergy to alfacalcidol or a component of your prescribed formulation. Seek emergency medical attention for difficulty breathing or swelling of the face or throat.Â
Taking more One-Alpha than prescribed may cause excessive calcium and phosphorus levels.
Because One-Alpha has a narrow therapeutic margin, even relatively small dosing errors may be important.
Symptoms of excessive dosing may include nausea, vomiting, constipation, excessive thirst, frequent urination, weakness, and unusual fatigue.
Severe cases may cause dehydration, confusion, kidney damage, or abnormal heart rhythms.
If you accidentally take more One-Alpha than prescribed, contact a poison control centre or healthcare provider immediately, even if symptoms have not developed.
Do not attempt to treat an overdose by drinking excessive amounts of water, particularly if you have chronic kidney disease or are following fluid restrictions.
Never double a missed dose or take extra One-Alpha. Seek immediate medical advice if an overdose is suspected.
One-Alpha is a potent vitamin D analogue that requires careful dosage selection and regular laboratory monitoring.
The most important treatment risks involve elevated calcium and phosphorus levels, which may contribute to kidney damage, abnormal heart rhythms, and calcium deposits in body tissues.
Patients with existing cardiovascular disease, kidney stones, sarcoidosis, or other significant medical conditions may require additional precautions.
One-Alpha should not be combined with other vitamin D preparations or excessive calcium supplements without medical guidance.
Contact your healthcare provider promptly if you develop persistent nausea, excessive thirst, frequent urination, muscle weakness, or unusual fatigue. Seek emergency medical attention for severe confusion, fainting, chest pain, or abnormal heart rhythms.
These warnings are not an exhaustive list of every possible precaution or medication interaction associated with One-Alpha. Always follow your healthcare provider’s instructions and attend all recommended medical appointments.
Yes. One-Alpha capsules and oral drops can generally be taken with or without food. Taking the medication with a meal may help patients remember their daily dose and may reduce mild stomach discomfort. One-Alpha is usually taken once daily, depending on the prescribed treatment plan. Patients with chronic kidney disease may need to follow specific dietary recommendations regarding calcium, phosphorus, and fluid intake. Avoid making significant changes to your diet or taking additional supplements without consulting your healthcare provider. One-Alpha can be taken with or without food. Follow your prescribed schedule and any dietary recommendations provided by your healthcare team.
If you forget to take a dose of One-Alpha, take it as soon as you remember, unless it is almost time for your next scheduled dose. If your next dose is approaching, skip the missed dose and continue with your regular dosing schedule. Do not take two doses together to make up for a missed dose. Taking additional alfacalcidol may increase blood calcium levels and cause potentially serious side effects, including nausea, vomiting, excessive thirst, frequent urination, and muscle weakness. If you miss several consecutive doses or are unsure when to restart treatment, contact your healthcare provider or pharmacist. Never double your One-Alpha dose to make up for a missed dose. Resume your regular schedule unless your healthcare provider advises otherwise.
One-Alpha is a vitamin D analogue, but it is not the same as ordinary vitamin D supplements. Routine nutritional vitamin D deficiency is usually treated with vitamin D3 (cholecalciferol) or vitamin D2 (ergocalciferol). One-Alpha is primarily used when the body has difficulty maintaining normal calcium metabolism because of certain medical conditions, particularly chronic kidney disease. Unlike conventional vitamin D supplements, alfacalcidol does not require the usual kidney activation step to become active vitamin D. This makes it useful for certain patients whose kidneys cannot effectively activate vitamin D. However, taking One-Alpha unnecessarily may cause dangerously high calcium levels. One-Alpha should not be used as a substitute for ordinary vitamin D supplements unless specifically prescribed by your healthcare provider.
Do not take additional calcium or vitamin D supplements unless your healthcare provider specifically recommends them. One-Alpha increases calcium absorption from the intestines. Combining it with excessive calcium or other vitamin D products may cause hypercalcemia, a condition in which calcium levels in the blood become too high. Possible symptoms include nausea, constipation, excessive thirst, frequent urination, muscle weakness, and confusion. Some patients with chronic kidney disease may require calcium supplements or phosphate binders as part of their treatment plan. However, the appropriate products and doses depend on laboratory results and individual medical needs. Your healthcare provider may monitor calcium, phosphorus, and parathyroid hormone levels to determine whether supplementation is necessary. Avoid taking additional calcium or vitamin D products with One-Alpha unless directed by your healthcare provider.
One-Alpha is commonly prescribed for certain mineral and bone disorders associated with chronic kidney disease. Healthy kidneys help convert vitamin D into its active form. When kidney function becomes impaired, this process may become less effective. One-Alpha helps address this problem because alfacalcidol can be converted into active vitamin D by the liver. However, patients with kidney disease may have difficulty regulating calcium and phosphorus levels. Excessive treatment can cause hypercalcemia, hyperphosphatemia, or abnormal calcium deposits in the kidneys and other tissues. For this reason, treatment requires careful dosage adjustments and regular blood tests. One-Alpha may be beneficial for selected patients with chronic kidney disease, but close medical monitoring is essential to prevent complications.
Yes. Hypercalcemia is one of the most important risks associated with One-Alpha treatment. Hypercalcemia occurs when calcium levels in the bloodstream become abnormally high. Because One-Alpha increases calcium absorption, excessive dosing or combining the medication with additional calcium and vitamin D products may raise calcium levels beyond the normal range. Symptoms may include persistent nausea, vomiting, constipation, excessive thirst, frequent urination, fatigue, and muscle weakness. Severe hypercalcemia may cause confusion, dehydration, kidney problems, or abnormal heart rhythms. Your healthcare provider will monitor blood calcium levels regularly and may reduce or temporarily discontinue treatment if necessary. Contact your healthcare provider promptly if you develop symptoms of high calcium. Seek emergency medical attention for severe confusion, fainting, or abnormal heart rhythms.
One-Alpha should generally be avoided during pregnancy unless a healthcare provider determines that treatment is clearly necessary. There is limited information about the safety of alfacalcidol during human pregnancy. Animal studies have identified potential reproductive risks, and excessive calcium levels during pregnancy may affect the developing baby. Because One-Alpha increases active vitamin D activity, treatment may cause hypercalcemia if the dosage is too high. Your healthcare provider will consider the severity of your medical condition, available treatment alternatives, and the potential benefits and risks before recommending One-Alpha. If treatment is considered necessary, careful monitoring of calcium and phosphorus levels may be required. Do not start, stop, or change One-Alpha treatment during pregnancy without consulting your healthcare provider.
Breastfeeding is not recommended during One-Alpha treatment according to the Canadian product monograph. Alfacalcidol or its active metabolites may pass into breast milk and potentially affect calcium metabolism in a nursing infant. Excessive vitamin D activity may increase an infant’s blood calcium levels, potentially causing feeding difficulties, vomiting, constipation, or other complications. If you are breastfeeding or planning to breastfeed, inform your healthcare provider before taking One-Alpha. Your healthcare provider will discuss whether treatment is necessary and recommend appropriate feeding arrangements or alternative treatments. Avoid breastfeeding while taking One-Alpha unless your healthcare team has assessed the situation and provided specific guidance.Â
One-Alpha is not authorized for use in children younger than 18 years in Canada. The safety and effectiveness of the medication in pediatric patients have not been established under the Canadian product monograph. Children require carefully regulated calcium and phosphorus levels for normal bone growth and development. Excessive vitamin D activity may cause elevated blood calcium, kidney complications, and other problems. Although alfacalcidol may be prescribed to children for certain metabolic bone disorders in other countries, such treatment requires specialist supervision. One-Alpha should not be given to children or adolescents unless an appropriately qualified specialist determines that treatment is necessary.Â
One-Alpha is not authorized for patients aged 65 years and older under its current Canadian product monograph because sufficient clinical data were not available to establish an indication for this age group. Older adults may also be more susceptible to complications associated with elevated calcium levels, particularly if they have reduced kidney function, heart disease, or take several medications. Possible complications include dehydration, confusion, weakness, kidney problems, and abnormal heart rhythms. If a healthcare provider considers alfacalcidol appropriate for an older patient, treatment requires an individualized assessment and careful monitoring. Patients aged 65 years and older should not start One-Alpha without specialist assessment and medical supervision.Â
Yes. One-Alpha may increase the risk of kidney stones when treatment causes excessive calcium levels in the blood or urine. Kidney stones are hard deposits that form when minerals accumulate in the urinary tract. Because One-Alpha increases calcium absorption, excessive dosing may lead to hypercalcemia or hypercalciuria. Hypercalciuria occurs when too much calcium is present in the urine. This may contribute to kidney stone formation in susceptible patients. Symptoms of kidney stones may include severe pain in the back or side, nausea, vomiting, or blood in the urine. Patients with chronic kidney disease or a previous history of kidney stones may require closer monitoring. Tell your healthcare provider if you have a history of kidney stones. Seek prompt medical attention if you develop severe flank pain, blood in your urine, or significant changes in urination.
Do not stop taking One-Alpha without consulting your healthcare provider. One-Alpha is often prescribed to manage ongoing abnormalities in calcium and bone metabolism associated with chronic kidney disease. Even if your calcium levels return to normal, the underlying condition may still require treatment. Stopping One-Alpha without medical guidance may allow calcium levels or parathyroid hormone levels to become abnormal again. However, your healthcare provider may reduce or temporarily discontinue treatment if blood tests show that calcium levels have become too high. The decision to continue, adjust, or stop treatment depends on laboratory results and your overall medical condition. Do not discontinue One-Alpha simply because your symptoms improve or your calcium levels become normal. Follow your healthcare provider’s treatment instructions.
Regular blood tests are essential during One-Alpha treatment because the medication affects calcium, phosphorus, and bone metabolism. Your healthcare provider may monitor calcium, phosphorus, magnesium, parathyroid hormone, kidney function, and alkaline phosphatase levels. Blood tests may be performed more frequently when treatment begins or the dosage is adjusted. Once mineral levels become stable, your healthcare provider may recommend a different monitoring schedule. These tests help determine whether One-Alpha is working effectively and whether the dosage needs to be changed. Importantly, excessive calcium or phosphorus levels may develop before noticeable symptoms appear. Attend all recommended blood tests while taking One-Alpha. Laboratory monitoring is essential for preventing serious complications.Â
Taking more One-Alpha than prescribed may cause dangerously high calcium and phosphorus levels. Possible symptoms include nausea, vomiting, constipation, excessive thirst, frequent urination, muscle weakness, and unusual fatigue. Severe overdose may cause dehydration, confusion, kidney damage, or abnormal heart rhythms. Because One-Alpha has a narrow therapeutic margin, even relatively small dosing errors may be important. If you accidentally take too much One-Alpha, contact your healthcare provider, poison control center, or emergency department immediately, even if you do not have symptoms. Do not attempt to manage an overdose by drinking excessive amounts of water, especially if you have chronic kidney disease or are following fluid restrictions. Seek immediate medical advice if an overdose is suspected. Do not take additional doses unless instructed by a healthcare professional.Â
One-Alpha should be stored according to its specific formulation because capsules, oral drops, and injections have different storage requirements. Proper storage helps maintain the medication’s stability, quality, and effectiveness throughout its shelf life. One-Alpha 0.25 microgram and 1 microgram capsules should be stored at temperatures below 25°C (77°F) and protected from direct sunlight. Keep the capsules in their original packaging and store them in a cool, dry place away from excessive heat and moisture. Avoid storing the medication in bathrooms or other areas where temperature and humidity frequently change. One-Alpha oral drops require refrigeration at temperatures between 2°C and 8°C (36°F and 46°F). Keep the bottle protected from direct sunlight and do not freeze the medication. Once the bottle has been opened, the oral drops should be used within four months. Any remaining medication should be discarded after this period, even if some liquid remains in the bottle. One-Alpha injection is generally stored, prepared, and administered by qualified healthcare professionals, particularly in patients receiving hemodialysis. The injectable formulation should be stored according to the manufacturer’s specific instructions to maintain its safety and effectiveness. Patients should not attempt to store or administer One-Alpha injections at home unless specifically instructed by their healthcare team. All One-Alpha formulations should be kept out of the sight and reach of children and pets to prevent accidental ingestion or exposure. Always check the expiration date before using the medication, and consult your pharmacist if you are unsure whether it has been stored correctly. Store One-Alpha capsules below 25°C (77°F), refrigerate oral drops between 2°C and 8°C (36°F and 46°F), and follow the manufacturer’s instructions for injectable formulations. Proper storage is essential for maintaining the medication’s quality and effectiveness.
No. One-Alpha is not considered an addictive medication. It contains alfacalcidol, a vitamin D analogue that helps regulate calcium and phosphorus metabolism. Unlike medications that affect the brain’s reward pathways, One-Alpha does not typically cause cravings, drug-seeking behavior, or psychological dependence. However, this does not mean that treatment can be stopped whenever symptoms improve. Patients with chronic kidney disease may require ongoing management of calcium and parathyroid hormone levels. Stopping One-Alpha without medical guidance may allow the underlying mineral imbalance to return. One-Alpha is not addictive, but treatment should only be stopped or adjusted under medical supervision.
Yes. One-Alpha may interact with certain medications, vitamins, and mineral supplements. Combining One-Alpha with other vitamin D products or excessive calcium supplements may increase the risk of hypercalcemia. Thiazide diuretics, such as hydrochlorothiazide, may also increase calcium levels when used with One-Alpha. Patients taking digoxin require particular caution because elevated calcium levels may increase the risk of abnormal heart rhythms. Certain anticonvulsants, including phenytoin, carbamazepine, and phenobarbital, may reduce the effects of alfacalcidol by increasing its metabolism. Magnesium-containing antacids and aluminum-containing medications may also require additional precautions, particularly in patients with impaired kidney function. Tell your healthcare provider and pharmacist about every medication, vitamin, mineral supplement, and herbal product you take before starting One-Alpha.
One-Alpha may be prescribed for ongoing management of calcium and bone metabolism disorders associated with chronic kidney disease. However, the appropriate treatment duration depends on the patient’s medical condition, response to treatment, and laboratory results. Long-term treatment requires careful monitoring because excessive calcium and phosphorus levels may contribute to kidney damage, cardiovascular problems, and abnormal calcium deposits in body tissues. Your healthcare provider will regularly evaluate whether continued treatment is necessary and whether the dosage remains appropriate. Do not continue taking One-Alpha at the same dosage indefinitely without recommended medical assessments. One-Alpha may be used for ongoing treatment when medically necessary, but long-term use requires regular laboratory monitoring and dosage reassessment.
| Generic name: | Alfacalcidol |
|---|---|
| Formulation: | Capsule |
| Strength(s): | 0.25mcg, 1mcg |
| Quantities Available: | 100 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering One-Alpha (alfacalcidol) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is common for prescription medications to ensure adequate management of chronic conditions without frequent refills.
Here’s what you need to know:
Dosage and Quantity: One-Alpha is available in 0.25 mcg and 1 mcg capsules. It is commonly prescribed in dosages ranging from 0.5 mcg to 3 mcg daily, depending on the patient’s condition and response.
For example, if your prescribed dosage is 1 mcg daily, you would order 90 capsules of 1 mcg (90 days x 1 capsule per day) or 360 capsules of 0.25 mcg (90 days x 4 capsules per day).
No, we do not sell alfacalcidol directly on our website. However, you can still enjoy low prices on One-Alpha, which contains alfacalcidol as an active ingredient. To purchase One-Alpha, you will need a valid prescription from your healthcare provider. We require this to dispense the medication safely and appropriately. You can submit your prescription by mailing it to us, faxing it, or uploading it through your online account.
Yes, we ship One-Alpha (alfacalcidol) to both the United States and Puerto Rico.
Watch how Online Pharmacies Canada is helping customers save money on their medications.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about One-Alpha (Alfacalcidol). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about One-Alpha (Alfacalcidol).
REVIEWS